39 Paul Tudor Jones II Incyte Trades
Paul Tudor Jones II's position in Incyte is currently worth $5.55 Million. That's 0.07% of their equity portfolio (364th largest holding). The first Incyte trade was made in Q4 2013. Since then Paul Tudor Jones II bought shares 23 more times and sold shares on seventeen occasions. The investor's estimated purchase price is $6.29 Million, resulting in a loss of 12%.
News about Incyte Corp. and Paul Tudor Jones II
Comparative Study: Biogen And Industry Competitors In Biotechnology Industry
In today''s rapidly changing and highly competitive business world, it is imperative for investors and industry observers to carefully assess companies befor...
BriaCell Reports Positive Breast Cancer Efficacy Data with Bria-IMT™ Immunotherapy Treatment at SITC Annual Meeting
PHILADELPHIA and VANCOUVER, British Columbia, Nov. 10, 2022 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or t...
There''s Money to Be Made With Vertex, Viatris, Incyte and Biogen
Analysis by Barron''s identifies these companies as undervalued Related Stocks: INCY , PFE , BIIB , VRTX , VTRS , BAC ,
Covid-19 roundup: Incyte, Novartis report PhIII flop for repurposed Jakafi; US to distribute first vaccines Monday
Is it time to cross off another theory for treating cytokine storms associated with Covid-19? Incyte's Jakafi — or Jakavi as its partner Novartis markets the...